We are live on ! Find out more

KITE

Kite Pharma, Inc.

KITE

Delisted

KITE was delisted on the 2nd of October, 2017.

62 hedge funds and large institutions have $260M invested in Kite Pharma, Inc. in 2014 Q3 according to their latest regulatory filings, with 60 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New

Increased

Maintained

Reduced

Closed

3,629% more capital invested

Capital invested by funds: $6.97M → $260M (+$253M)

1,900% more first-time investments, than exits

New positions opened: 60 | Existing positions closed: 3

1,140% more funds holding

Funds holding: 5 → 62 (+57)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

Holders

Holders Change

+57

Holders Change %

+1,140%

% of All Funds

1.8%

Holding in Top 10

Holding in Top 10 Change

Holding in Top 10 Change %

% of All Funds

0.03%

New

Increased

Reduced

Closed

Calls

–

Puts

–

Net Calls

–

Net Calls Change

–

Top Buyers

Rank	Fund	Capital Flow
1	Capital Research Global Investors Los Angeles, California	+$59.1M
2	DM Deerfield Management New York	+$25M
3	Fidelity Investments Boston, Massachusetts	+$24.5M
4	JP Morgan Chase New York	+$18.6M
5	SFM Soros Fund Management New York	+$16.3M

Top Sellers

Rank	Fund	Capital Flow
1	Alyeska Investment Group Chicago, Illinois	-$1.82M
2	EA Emerald Advisers Leola, Pennsylvania	-$1.08M
3	EMFAT Emerald Mutual Fund Advisers Trust Leola, Pennsylvania	-$513K
4	Citadel Advisors Miami, Florida	-$269K

#	Name	Holding	Trade Value	Shares Change	Change in Stake
26	26 Geode Capital Management Boston, Massachusetts	$1.14M	+$987K	+39,900	New
27	27 Jane Street New York	$1.01M	+$874K	+35,346	New
28	28 Federated Hermes Pittsburgh, Pennsylvania	$855K	+$742K	+30,000	New
29	BA 29 BlackRock Advisors Wilmington, Delaware	$849K	+$737K	+29,777	New
30	30 Bank of New York Mellon New York	$825K	+$716K	+28,940	New
31	31 Royal Bank of Canada Toronto, Ontario, Canada	$821K	+$713K	+28,800	New
32	32 Citadel Advisors Miami, Florida	$805K	-$269K	-10,881	-28%
33	TCIM 33 TIAA CREF Investment Management New York	$762K	+$661K	+26,731	New
34	PC 34 PointState Capital New York	$713K	+$619K	+25,000	New
35	SAM 35 Shikiar Asset Management New York	$712K	+$619K	+25,000	New
36	BIM 36 BlackRock Investment Management Wilmington, Delaware	$666K	+$578K	+23,365	New
37	37 Northern Trust Chicago, Illinois	$652K	+$567K	+22,907	New
38	38 Morgan Stanley New York	$636K	+$552K	+22,297	New
39	CNB 39 City National Bank Beverly Hills, California	$570K	+$495K	+20,000	New
40	MIG 40 Mariner Investment Group Harrison, New York	$470K	+$408K	+16,507	New
41	41 California State Teachers Retirement System (CalSTRS) West Sacramento, California	$453K	+$393K	+15,900	New
42	MLICM 42 Metropolitan Life Insurance Company (MetLife) New York	$309K	+$269K	+10,860	New
43	NFA 43 Nationwide Fund Advisors Columbus, Ohio	$291K	+$253K	+10,206	New
44	ACPU 44 Arrowgrass Capital Partners (US) Dover, Delaware	$285K	+$247K	+10,000	New
45	WMSA 45 Weiss Multi-Strategy Advisers New York	$285K	+$247K	+10,000	New
46	TA 46 Teachers Advisors New York	$229K	+$199K	+8,040	New
47	47 Wells Fargo San Francisco, California	$185K	+$161K	+6,500	New
48	48 SG Americas Securities New York	$137K	+$119K	+4,800	New
49	U 49 UBS Zurich, Switzerland	$99K	+$85.6K	+3,459	New
50	SO 50 STRS Ohio Columbus, Ohio	$86K	+$74.2K	+3,000	New

KITE Hedge Fund Activity: Q3 2014 in Review

62 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Kite Pharma, Inc. (KITE) for Q3 2014, worth a combined $260M — up 3,629% from $6.97M a quarter earlier.

Buyers outnumbered sellers: 60 funds opened new KITE positions and 3 closed out — a net gain of 57 holders — while 1 added to existing stakes and 1 trimmed.

The largest buyer was Capital Research Global Investors, opening a new position worth an estimated $59.1M. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $1.82M sold.

62 institutional investors held Kite Pharma, Inc. (KITE) as of Q3 2014, up from 5 in Q2 2014.
Funds reported $260M of Kite Pharma, Inc. stock for Q3 2014, up 3,629% quarter-over-quarter.
60 funds opened new Kite Pharma, Inc. positions in Q3 2014 and 3 closed out, a net change of +57 holders.
The largest Kite Pharma, Inc. buyer in Q3 2014 was Capital Research Global Investors, an estimated $59.1M added.
The largest Kite Pharma, Inc. seller in Q3 2014 was Alyeska Investment Group, an estimated $1.82M sold.

Based on aggregated 13F filings for Q3 2014.

Kite Pharma, Inc. KITE